Andrew Hollman Meyer Sells 3,333 Shares of Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 3,333 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $30.00, for a total value of $99,990.00. Following the transaction, the insider directly owned 84,974 shares of the company’s stock, valued at approximately $2,549,220. This represents a 3.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Andrew Hollman Meyer also recently made the following trade(s):

• On Tuesday, October 28th, Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock. The stock was sold at an average price of $30.06, for a total transaction of $500,949.90.

Janux Therapeutics Price Performance

JANX stock traded up $1.82 during midday trading on Friday, hitting $29.28. The stock had a trading volume of 1,318,767 shares, compared to its average volume of 1,121,612. The business has a fifty day moving average price of $25.50 and a two-hundred day moving average price of $25.19. Janux Therapeutics, Inc. has a 1-year low of $21.73 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.21. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. On average, analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on JANX. Guggenheim started coverage on shares of Janux Therapeutics in a report on Wednesday, September 3rd. They issued a “buy” rating and a $72.00 price target on the stock. Stifel Nicolaus reissued a “buy” rating and set a $45.00 price target on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Piper Sandler initiated coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $42.00 price objective on the stock. Barclays lifted their price target on Janux Therapeutics from $47.00 to $48.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $79.17.

Institutional Trading of Janux Therapeutics

Hedge funds have recently bought and sold shares of the stock. US Bancorp DE increased its stake in shares of Janux Therapeutics by 2,402.9% in the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after purchasing an additional 1,658 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares during the period. Virtus Investment Advisers LLC increased its stake in Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after buying an additional 1,011 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after buying an additional 2,502 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in shares of Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after purchasing an additional 820 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.